CPA
HALO icon

Capital Performance Advisors’s Halozyme HALO Stock Holding History

Capital Performance Advisors’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-59
Closed -$3.38K – 1207
2024
Q3 		$3.38K Buy
+59
New +$3.38K ﹤0.01% 1299

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital Performance Advisors's HALO Position: Q4 2024 in Review

Capital Performance Advisors sold out of Halozyme (HALO) in Q4 2024, closing a stake of 59 shares — an estimated $3.38K sold.

Capital Performance Advisors first reported a position in HALO in Q3 2024 and held it in 1 quarter. The position peaked at $3.38K in Q3 2024. 508 funds tracked by Wall St. Rank hold HALO as of Q4 2024.

  • Capital Performance Advisors reported no remaining Halozyme position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 59 Halozyme shares in Q4 2024, an estimated $3.38K.
  • Capital Performance Advisors first reported a position in Halozyme in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Halozyme position peaked at $3.38K in Q3 2024.
  • 508 funds tracked by Wall St. Rank held Halozyme as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.